Royal Bank Of Canada Atreca, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.13 - $0.38 $100 - $292	770 New	770 $0
Q2 2023 Aug 14, 2023	BUY	$0.88 - $1.22 $118 - $164	135 Added 15.45%	1,009 $0
Q1 2023 May 15, 2023	BUY	$0.91 - $1.82 $728 - $1,456	800 Added 1081.08%	874 $0
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $1,590 - $2,740	-1,000 Reduced 93.11%	74 $0
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $931 - $1,940	-597 Reduced 35.73%	1,074 $2,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $5,916 - $19,110	-3,675 Reduced 68.74%	1,671 $5,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $7,809 - $17,115	2,721 Added 103.66%	5,346 $15,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $3,790 - $7,002	772 Added 41.66%	2,625 $16,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $14,490 - $25,571	1,853 New	1,853 $16,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.